

Disclosure of Value Transfers

Methodological Note

Country	Ireland
Entity Name	Fresenius Kabi Limited
Legal Basis for Disclosure	Medicines for Europe Code of Conduct on Interactions with the Healthcare Community, published February 2015 Updated in January 2016
Reporting Period	2022
Currency of disclosed values	 All values are disclosed in ⊠ EUR □ [local currency, if required]
Scope of disclosure	The disclosure covers all interactions with HCPs, HCOs and Patient Organizations medicines related to generics medicinal products. Interactions related to biosimilars, medical devices or nutrition products are not disclosed.
Value identification and Recognition	All values disclosed are based on value transfers actually made within the respective category. Such value transfers have been made to a specific recipient as booked in the respective reporting period.
Data disclosed for	 All values are disclosed for ☑ Recipients which have been engaged by entity (e.g. Medicines for Europe) □ Recipients which have their residence in the country (e.g. EFPIA)
VAT and other taxes Disclosure location:	All amounts are disclosed include VAT or similar service taxes, where such apply on the transaction. https://www.fresenius-kabi.com/ie/company/transparency-initiative



Disclosure of Value Transfers

Value category: "Meetings, educational support and site visits of HCPs"	The company discloses value transfers in this category as per Option 2 of the Medicines for Europe Transparency Requirements: Aggregate total amount of support provided to Healthcare Professionals per individual conference or meeting as follows: • Sponsorship for attending a third party organised congress (as per section 4.4):
	 name of congress, aggregated amount spent for the congress, including the number of Healthcare Professionals financially supported to attend
	 Site visits (as per section 4.5): aggregated amount spent, including the number of Healthcare Professionals financially supported to attend.
	• Company organised meeting: aggregated amount spent, including the number of Healthcare Professionals financially supported to attend.
Other Remarks	For value categories related to HCPs, aggregate values have been disclosed where the consent of a multiple number of HCP could not be obtained. Fees paid in connection with research & development activities or
	market research have not been disclosed.